Latest / Decera Clinical Education Oncology Podcast
Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer
In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including:
Challenges with the pathologic testing for HER2-low expression
Optimal treatment of patients with HER2-low advanced breast cancer
Role of TROP-2–targeted therapies
Management of ADC-associated adverse events to optimize treatment outcomes
ADCs on the horizon for patients with advanced breast cancer
Presenters:
Sara M. Tolaney…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.